Showing 991-1000 of 1211 results for "".
- Stanford University Study Finds Ovarian Cancer Drug Can Affect the Eyeshttps://modernod.com/news/stanford-university-study-finds-ovarian-cancer-drug-can-affect-the-eyes/2482510/A study presented at the American Academy of Ophthalmology (AAO) meeting in Chicago found Mirvetuximab soravtansine (Elahere) is associated with corneal toxicity and related vision changes. Mirvetuximab is part of an emerging class of anti-cancer drugs called antibody-drug conjugates. A
- Life Biosciences Presents New Data on Novel Gene Therapy at AAOhttps://modernod.com/news/life-biosciences-presents-new-data-on-novel-gene-therapy-at-aao/2482505/Life Biosciences announced new data at the 2024 American Association of Ophthalmology (AAO) annual meeting on its gene therapy for optic neuropathies. According to Life Biosciences, the data replicates earlier findings in nonhuman primates (NHPs) and provides insights into the dosing and tim
- Study Targets Early Signs of Vision Loss in Diabetic Patientshttps://modernod.com/news/study-targets-early-signs-of-vision-loss-in-diabetic-patients/2482408/The University of Houston (UH) College of Optometry is embarking on a study, backed by a $3.3 million grant from the National Eye Institute, to investigate the progression of vision loss in patients with prediabetes and diabetes. The study, led by Associate Professor Wendy Harrison, aims to ident
- Latinos En Optometry Launches Redesigned Website and New Domain Namehttps://modernod.com/news/latinos-en-optometry-launches-redesigned-website-and-new-domain-name/2482291/Latinos en Optometry, a non-profit association dedicated to gaining a broader representation of Latinos and Spanish-speaking professionals within the optometry and larger eye care professional community, announced the launch of its redesigned website and new domain name,
- EyeCRO Presents Phase 2 Results for MiDROPS Platformhttps://modernod.com/news/eyecro-presents-phase-2-results-for-midrops-platform/2482276/EyeCRO has announced that data from the first clinical application of its MiDROPS (Microemulsion Drug Ocular Penetration System) platform technology was presented by Telios Pharma at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Seattle, WA. The presentation
- Isarna Therapeutics Announces Phase 2 Clinical Data Presentations at Upcoming Ophthalmology Conferenceshttps://modernod.com/news/isarna-therapeutics-announces-phase-2-clinical-data-presentations-at-upcoming-ophthalmology-conferences/2482263/Isarna Therapeutics announced upcoming oral presentations at the OIS Retina Innovation Summit on May 4 and the Association for Research in Vision and Ophthalmology (ARVO) meeting on May 7, both in Seattle. Isarna’s Chief Medical Officer, Prof. Marion R. Munk, will present upd
- Vesigen to Present New Preclinical Data on Ophthalmology Applications of Engineered ARMMs at ARVOhttps://modernod.com/news/vesigen-to-present-new-preclinical-data-on-ophthalmology-applications-of-engineered-armms-at-arvo/2482262/Vesigen Therapeutics announced that the company will be presenting two posters sharing new preclinical data from its engineered ARMMs platform at the upcoming Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle, from May 5-9. Vesigen’s techno
- Johnson & Johnson to Debut EYE-RD Global Registry at ARVOhttps://modernod.com/news/johnson-johnson-to-debut-eye-rd-global-registry-at-arvo/2482261/Johnson & Johnson announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place in Seattle from May 5–9, 2024. The company's two oral presentations wil
- New Ocular Telehealth Program Enables Diabetic Retinopathy Screeninghttps://modernod.com/news/new-ocular-telehealth-program-enables-diabetic-retinopathy-screening/2482241/Visionix USA and 20/20NOW have launched an ocular telehealth program to enable diabetic retinopathy screening. The new technology will be presented at the American Telemedicine Association (ATA)’s 2024 Nexus Conference and Expo in Arizona in May. Visionix and 20/20NOW will be offe
- Ocugen Completes Dosing in Phase 1/2 Trial of OCU410 for Geographic Atrophyhttps://modernod.com/news/ocugen-advances-armada-trial-of-ocu410-to-treat-patients-with-geographic-atrophy/2482238/Ocugen announced dosing is complete in the second cohort of its phase 1/2 ArMaDa trial of OCU410, an adeno-associated viral vector 5 human RORA (AAV5-hRORA) gene therapy being developed for geographic atrophy (GA). Up to 13